FDA to discuss Novartis' TOBI Podhaler
14:20 EDT 9 Jul 2012 | BioCentury
FDA's Anti-Infectives Drugs Advisory Committee will meet on Sept. 5 to discuss an NDA from Novartis AG (NYSE:NVS; SIX:NOVN) for TOBI Podhaler to treat Pseudomonas aeruginosa lung infections in cystic fibrosis patients. Novartis disclosed in its 1Q12..
Original Article: FDA to discuss Novartis' TOBI Podhaler
More From BioPortfolio on "FDA to discuss Novartis' TOBI Podhaler"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
